Literature DB >> 17230468

Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.

Anne M Landau1, Edouard Kouassi, Rosmarie Siegrist-Johnstone, Julie Desbarats.   

Abstract

Defects in the ubiquitin-proteasome system have been implicated in Parkinson's Disease (PD). Recently, a rat model of PD was developed using a synthetic proteasome inhibitor (PSI), (Z-lle-Glu(OtBu)-Ala-Leu-al). We attempted to transfer this model to mouse studies, where genetics can be more readily investigated due to the availability of genetically modified mice. We treated C57BL/6 (B6) mice with six intraperitoneal injections of 6 mg/kg PSI in 50 mul of 70% ethanol over a 2-week-period. We found significant decreases in nigrostriatal dopamine in PSI-treated mice compared with saline-treated mice. However, we observed similar decreases in the ethanol-treated vehicle control group. Administration of ethanol alone led to significant long-term alterations in dopamine levels. Ethanol significantly eclipses the effects of PSI in the dopamine system, and therefore is a confounding vehicle for this model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230468     DOI: 10.1002/mds.21306

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  Ubiquitin-proteasome system as a modulator of cell fate.

Authors:  Simon J Thompson; Liam T Loftus; Michelle D Ashley; Robert Meller
Journal:  Curr Opin Pharmacol       Date:  2007-11-05       Impact factor: 5.547

2.  Alcohol drinking and risk of Parkinson's disease: a case-control study in Japan.

Authors:  Wakaba Fukushima; Yoshihiro Miyake; Keiko Tanaka; Satoshi Sasaki; Chikako Kiyohara; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  BMC Neurol       Date:  2010-11-05       Impact factor: 2.474

3.  Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study.

Authors:  Stefano Delli Pizzi; Cosmo Rossi; Vincenzo Di Matteo; Ennio Esposito; Simone Guarnieri; Maria Addolorata Mariggiò; Raffaella Franciotti; Massimo Caulo; Astrid Thomas; Marco Onofrj; Armando Tartaro; Laura Bonanni
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

4.  Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Authors:  Nadia Stefanova; Walter A Kaufmann; Christian Humpel; Werner Poewe; Gregor K Wenning
Journal:  Acta Neuropathol       Date:  2012-04-11       Impact factor: 17.088

Review 5.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

Review 6.  Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown.

Authors:  Mingxia Bi; Xixun Du; Qian Jiao; Xi Chen; Hong Jiang
Journal:  Cell Death Dis       Date:  2021-02-04       Impact factor: 8.469

Review 7.  Role of the ubiquitin proteasome system in Parkinson's disease.

Authors:  Kah-Leong Lim; Jeanne M M Tan
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

8.  Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.

Authors:  Thea P Lillethorup; Andreas N Glud; Aage K O Alstrup; Ove Noer; Erik H T Nielsen; Anna C Schacht; Natalie Landeck; Deniz Kirik; Dariusz Orlowski; Jens Christian H Sørensen; Doris J Doudet; Anne M Landau
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

Review 9.  Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

Authors:  Bin Peng; Qiang Yang; Rachna B Joshi; Yuancai Liu; Mohammed Akbar; Byoung-Joon Song; Shuanhu Zhou; Xin Wang
Journal:  Int J Mol Sci       Date:  2020-03-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.